Auna S.A. Class A (AUNA) AI Stock Analysis

Compare

259 Followers

Top Page

Auna S.A. Class A

(NYSE:AUNA)

Rating:58Neutral

Price Target:

$6.50

▲(4.67%Upside)

The overall score reflects a strong financial performance with solid revenue growth and profitability improvements. However, technical analysis shows bearish momentum, and valuation metrics are reasonable but not compelling. Continued focus on reducing leverage and enhancing market sentiment could improve the stock's outlook.

Auna S.A. Class A (AUNA) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$459.62M

Dividend YieldN/A

Average Volume (3M)35.35K

Price to Earnings (P/E)10.8

Beta (1Y)1.01

Revenue Growth6.97%

EPS GrowthN/A

CountryUS

Employees14,605

SectorGeneral

Sector StrengthN/A

IndustryMedical - Care Facilities

Share Statistics

EPS (TTM)0.19

Shares Outstanding30,095,388

10 Day Avg. Volume55,840

30 Day Avg. Volume35,354

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)1.54

Price to Sales (P/S)0.00

P/FCF Ratio154.07

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$7.90

Price Target Upside27.21% Upside

Rating ConsensusHold

Number of Analyst Covering1

Auna S.A. Class A Business Overview & Revenue Model

Company DescriptionAuna S.A. Class A (AUNA) is a leading healthcare provider in Latin America, primarily operating in Peru and Colombia. The company offers a wide range of medical services through its network of hospitals, clinics, and specialized healthcare facilities. Auna is dedicated to delivering high-quality healthcare solutions and improving patient outcomes by leveraging advanced medical technology and skilled healthcare professionals.

How the Company Makes MoneyAuna S.A. generates revenue primarily through the provision of healthcare services, including hospital stays, outpatient care, and specialized medical treatments. The company operates a network of hospitals and clinics where it charges patients and insurance companies for medical services rendered. Additionally, Auna may receive income from partnerships with healthcare insurers and government healthcare programs, which subsidize or directly pay for services provided to covered patients. The company's focus on expanding its healthcare facilities and services helps drive patient volume and, consequently, revenue growth.

Auna S.A. Class A Earnings Call Summary

Earnings Call Date:May 20, 2025

(Q3-2024)

% Change Since: -11.29%|

Next Earnings Date:Aug 20, 2025

Earnings Call Sentiment Positive

The earnings call highlighted significant growth in adjusted EBITDA, revenue growth in key markets like Mexico and Peru, and improvement in debt leverage. However, challenges in Colombia, specifically related to provisions for impairment losses, pose a concern. Overall, the positive developments in various regions and financial metrics outweigh the challenges faced in Colombia.

Q3-2024 Updates

Positive Updates

Record Adjusted EBITDA Growth

Adjusted EBITDA increased by 23% on an FX-neutral basis with a margin expansion of 1.4 percentage points. Mexico and Peru reached record highs with Mexico's adjusted EBITDA increasing by 34%.

Revenue Growth in Key Markets

Regional platform revenues increased by 13% year-over-year to PEN 1.1 billion, led by Mexico and Peru, which grew 16% and 13%, respectively.

Debt Leverage Improvement

Net debt to adjusted EBITDA ratio fell below 4x to 3.7x, marking the eighth consecutive quarter of improving leverage since the acquisition in 2022.

Positive Performance in Peru

Revenue grew 13% with adjusted EBITDA increasing nearly 50%, and margin expanded by 5.3 percentage points to 21.6%.

Negative Updates

Challenges in Colombia

Adjusted EBITDA decreased by 18% due to increased provisions for impairment losses, impacting the margin which decreased by 4.5 percentage points to 12.4%.

Provision for Impairment Losses

Increased provision for impairment losses in Colombia by PEN 16 million due to less predictable payments from payers.

Company Guidance

During the third quarter 2024 earnings call for Auna, the company provided guidance that highlighted significant financial metrics and strategic outlooks. Adjusted EBITDA increased by 23% year-over-year on an FX-neutral basis, with margins expanding by 1.4 percentage points. In terms of regional performance, Mexico and Peru saw record highs in adjusted EBITDA, with Mexico's adjusted EBITDA increasing by 34% and its margin growing by 4.7 percentage points to nearly 36%. Auna's overall regional platform revenues grew by 13% to PEN 1.1 billion, driven by 16% growth in Mexico and 13% in Peru. The company's debt leverage improved, with the net debt to adjusted EBITDA ratio falling below 4x for the first time since the acquisition in Mexico, marking the eighth consecutive quarter of leverage reduction. Additionally, consolidated revenue grew 13% and adjusted EBITDA increased 23% on an FX-neutral basis, while the margin improved by 1.4 percentage points to over 22%. The company remains optimistic about its long-term growth strategies in Mexico and Colombia, with a focus on implementing the AunaWay and expanding its oncological services.

Auna S.A. Class A Financial Statement Overview

Summary

Auna S.A. exhibits solid financial health with strong revenue growth and improved profitability margins, reflecting effective cost management and operational efficiencies. While leverage remains a concern, the company's ability to generate cash flow and manage debt levels has improved. Continued focus on enhancing return on equity and maintaining cash flow strength will be crucial for future stability and growth.

Income Statement

Positive

Auna S.A. demonstrated a strong revenue growth of 13.17% from 2023 to 2024, continuing a positive trend with a significant leap from 2022. The gross profit margin improved to 39.32%, while the net income turned positive after two consecutive years of losses, resulting in a net profit margin of 2.51%. EBIT and EBITDA margins also showed healthy improvements, indicating enhanced operational efficiency.

Balance Sheet

Positive

The company maintains a relatively high debt-to-equity ratio of 2.6, indicating significant leverage but a reduction from prior years. The equity ratio improved to 20.86%, reflecting better capital structure management. However, the return on equity remains modest at 7.47%, suggesting room for improvement in generating returns for shareholders.

Cash Flow

Positive

Auna S.A. experienced a robust 38.36% growth in free cash flow in 2024, supported by strong operating cash flow. The operating cash flow to net income ratio is a healthy 6.06, showcasing efficient cash conversion. The free cash flow to net income ratio of 5.24 highlights the company's ability to generate cash relative to its net profit.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
4.39B	3.88B	2.45B	1.92B	1.44B
	Gross Profit
1.73B	1.44B	879.70M	686.93M	529.43M
	EBIT
783.76M	560.34M	254.59M	108.14M	118.42M
	EBITDA
975.27M	647.30M	299.14M	170.15M	108.36M
	Net Income Common Stockholders
110.27M	-253.92M	-85.61M	-26.47M	-7.10M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
335.97M	334.26M	208.69M	138.77M	343.45M
	Total Assets
7.08B	7.69B	6.59B	2.82B	2.65B
	Total Debt
3.77B	3.92B	3.51B	1.49B	1.35B
	Net Debt
3.53B	3.68B	3.30B	1.35B	1.01B
	Total Liabilities
5.46B	5.91B	5.04B	2.28B	2.00B
	Stockholders Equity
1.48B	1.47B	1.06B	495.82M	600.93M
Cash Flow		Free Cash Flow
577.64M	417.25M	10.67M	-106.03M	27.38M
	Operating Cash Flow
668.50M	582.41M	162.64M	183.34M	156.30M
	Investing Cash Flow
-236.82M	-173.15M	-3.21B	-291.99M	-125.93M
	Financing Cash Flow
-418.12M	-370.00M	3.13B	-102.13M	272.70M

Auna S.A. Class A Technical Analysis

Technical Analysis Sentiment

Negative

Last Price6.21

Price Trends

50DMA

6.74

Negative

100DMA

7.25

Negative

200DMA

7.17

Negative

Market Momentum

MACD

-0.16

Positive

RSI

34.37

Neutral

STOCH

26.59

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUNA, the sentiment is Negative. The current price of 6.21 is below the 20-day moving average (MA) of 6.45, below the 50-day MA of 6.74, and below the 200-day MA of 7.17, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 34.37 is Neutral, neither overbought nor oversold. The STOCH value of 26.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AUNA.

Auna S.A. Class A Peers Comparison

Overall Rating

UnderperformOutperform

Sector (57)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BTMD	67 Neutral	$151.65M	6.48	-7.92%	―	6.44%	322.20%
AUNA	58 Neutral	$459.62M	10.84	9.93%	―	6.97%	―
Sector *	57 Neutral	$5.49B	24.48	-31.27%	5.76%	10.94%	-29.91%
DCGO	52 Neutral	$157.58M	12.68	-0.21%	―	-26.00%	-103.18%
CMPS	47 Neutral	$429.89M	―	-60.67%	―	―	3.88%
PIII	43 Neutral	$44.92M	―	-131.17%	―	9.79%	-47.01%
CCM	39 Underperform	$25.29M	―	14.03%	―	-29.82%	-2.57%

* General Sector Average

Performance Comparison

AUNA

Auna S.A. Class A

6.21

-1.48

-19.25%

CCM

Concord Medical Services

5.82

-5.88

-50.26%

CMPS

COMPASS Pathways

4.63

-1.66

-26.39%

DCGO

DocGo

1.59

-1.46

-47.87%

PIII

P3 Health Partners

6.25

-22.25

-78.07%

BTMD

biote

3.96

-3.39

-46.12%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.